In addition, Benoit et al. [77] proposed an AOP for breast cancer (i.e., the AO in the case) whose MIE is the activation of the AhR (aryl hydrocarbon receptor), a pivotal molecule in exposure to many carcinogenic compounds, including PAHs. The gene discussed is AHR; the disease is breast carcinoma.